Cover Image
市場調查報告書

BIND Therapeutics, Inc.- 產品平台檢討

BIND Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 305684
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
BIND Therapeutics, Inc.- 產品平台檢討 BIND Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 31 Pages
簡介

BIND Therapeutics, Inc.是總公司設立於美國的奈米醫學技術之開發企業,正在開發針對癌症,心血管系統疾病,發炎疾病等之臨床試驗前階段候補物質並將之商品化。利用該公司的奈米工程技術,可減少健康組織的暴露,同時也飛躍性大幅增加將藥物送達到腫瘤細胞的能力,克服了現有藥物的極限。

本報告提供BIND Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

BIND Therapeutics, Inc.的基本資料

  • BIND Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

BIND Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

BIND Therapeutics, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

BIND Therapeutics, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

BIND Therapeutics, Inc.:藥物簡介

  • docetaxel
  • AZD-2811
  • Small Molecule 1 for Oncology
  • Small Molecule 2 for Oncology
  • Small Molecule to Inhibit Kinesin Spindle Protein for Cancer
  • Small Molecule to Inhibit PLK1 for Cancer
  • vincristine sulfate

BIND Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

BIND Therapeutics, Inc.:最近的開發平台資訊

BIND Therapeutics, Inc.:暫停開發中的計劃

BIND Therapeutics, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07078CDB

Summary

Global Markets Direct's, 'BIND Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the BIND Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BIND Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BIND Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BIND Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BIND Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate BIND Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BIND Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BIND Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BIND Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BIND Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BIND Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BIND Therapeutics, Inc. Snapshot
    • BIND Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • BIND Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • BIND Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • BIND Therapeutics, Inc. - Pipeline Products Glance
    • BIND Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • BIND Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • BIND Therapeutics, Inc. - Drug Profiles
    • docetaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZD-2811
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Kinesin Spindle Protein for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit PLK1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vincristine sulfate
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BIND Therapeutics, Inc. - Pipeline Analysis
    • BIND Therapeutics, Inc. - Pipeline Products by Target
    • BIND Therapeutics, Inc. - Pipeline Products by Route of Administration
    • BIND Therapeutics, Inc. - Pipeline Products by Molecule Type
    • BIND Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • BIND Therapeutics, Inc. - Recent Pipeline Updates
  • BIND Therapeutics, Inc. - Dormant Projects
  • BIND Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BIND Therapeutics, Inc., Key Information
  • BIND Therapeutics, Inc., Key Facts
  • BIND Therapeutics, Inc. - Pipeline by Indication, 2015
  • BIND Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • BIND Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • BIND Therapeutics, Inc. - Phase II, 2015
  • BIND Therapeutics, Inc. - Preclinical, 2015
  • BIND Therapeutics, Inc. - Pipeline by Target, 2015
  • BIND Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • BIND Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • BIND Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • BIND Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • BIND Therapeutics, Inc. - Dormant Developmental Projects,2015

List of Figures

  • BIND Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • BIND Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • BIND Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • BIND Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • BIND Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • BIND Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top